4D Molecular's Fabry program hold could benefit Sangamo

Last week’s US Food and Drug Administration (FDA) clinical hold on genetic medicines company 4D Molecular Therapeutics (Nasdaq: FDMT) Fabry disease (FD) gene therapy program (4D-310) could benefit fellow US drugmaker Sangamo Therapeutics (Nasdaq: SGMO).

4DMT and Sangamo are the leading developers in the Fabry disease space, and with the FDA’s clinical hold, the future of 4DMT’s program remains uncertain. As a result, Sangamo is expected to gain a significant market share, as its therapy will likely achieve approval before 4DMT’s therapy, says analytics company GlobalData.

4DMT paused the enrolment of patients to two of its trials for 4D-310 in January 2023, following significant adverse events where three patients experienced kidney issues; however, these were treated and resolved in a four-week period.